Objectives: Hepatitis C virus (HCV) infection is a well-documented risk factor for
hepatocellular carcinoma (HCC). Seven HCV genotypes have been classified, and the …

The prevalence of hepatitis C virus (HCV) in Asia is 0.5% to 4.7%, with three different
genotypes predominating, depending on the geographic region: genotype 1b in East Asia …

Objective Very few cost-utility analyses have either evaluated direct-acting antivirals (DAAs)
on hepatitis C virus (HCV) genotype 6 patients or undertaken societal perspective. Recently …

Background Liver fibrosis and its sequel cirrhosis represent a major health care burden, and
assessment of fibrosis by biopsy is gradually being replaced by noninvasive methods. In …

Objectives: Hepatitis C genotype 6 (HCV-GT6) is one of the most prevalent genotypes in
Southeast Asia. Ledipasvir and sofosbuvir fixed-dose combination (LDV/SOF FDC) for 12 …

Hepatitis C virus (HCV) chronically infects more than 175 million people globally and is also
one of the leading causes of liver cirrhosis and hepatocellular carcinoma worldwide. 1, 2 …

Hepatitis C is a chronic infectious disease that causes liver disease. It remains a significant
public health problem, with an estimated 58 million people infected worldwide. Recent …

Over the past few decades, the race against the treatment strategies of infectious HCV has
gained a lot of momentum. These treatments include several therapies like Ribavirin, INF-α …

Background and aim There have been significant advancements during the last few years,
with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high …